It's been a good week for Sundrug Co.,Ltd. (TSE:9989) shareholders, because the company has just released its latest half-yearly results, and the shares gained 8.8% to JP¥4,216. SundrugLtd reported JP¥433b in revenue, roughly in line with analyst forecasts, although statutory earnings per share (EPS) of JP¥63.78 beat expectations, being 3.7% higher than what the analysts expected. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results.
Following the latest results, SundrugLtd's six analysts are now forecasting revenues of JP¥894.2b in 2027. This would be a modest 4.3% improvement in revenue compared to the last 12 months. Per-share earnings are expected to accumulate 5.0% to JP¥284. Before this earnings report, the analysts had been forecasting revenues of JP¥893.1b and earnings per share (EPS) of JP¥282 in 2027. So it's pretty clear that, although the analysts have updated their estimates, there's been no major change in expectations for the business following the latest results.
See our latest analysis for SundrugLtd
The analysts reconfirmed their price target of JP¥4,681, showing that the business is executing well and in line with expectations. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. Currently, the most bullish analyst values SundrugLtd at JP¥5,600 per share, while the most bearish prices it at JP¥3,970. This shows there is still a bit of diversity in estimates, but analysts don't appear to be totally split on the stock as though it might be a success or failure situation.
One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. It's clear from the latest estimates that SundrugLtd's rate of growth is expected to accelerate meaningfully, with the forecast 8.7% annualised revenue growth to the end of 2027 noticeably faster than its historical growth of 6.5% p.a. over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 3.3% per year. Factoring in the forecast acceleration in revenue, it's pretty clear that SundrugLtd is expected to grow much faster than its industry.
The most important thing to take away is that there's been no major change in sentiment, with the analysts reconfirming that the business is performing in line with their previous earnings per share estimates. Fortunately, they also reconfirmed their revenue numbers, suggesting that it's tracking in line with expectations. Additionally, our data suggests that revenue is expected to grow faster than the wider industry. The consensus price target held steady at JP¥4,681, with the latest estimates not enough to have an impact on their price targets.
Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. At Simply Wall St, we have a full range of analyst estimates for SundrugLtd going out to 2029, and you can see them free on our platform here..
Even so, be aware that SundrugLtd is showing 1 warning sign in our investment analysis , you should know about...
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.